edical or veterinary science and hygiene (A61)

A   Human necessities(303198)
A61            edical or veterinary science; hygiene(129366)
ethod of long-term individual control of arterial pressure and pulse // 2607792
FIELD: medicine.SUBSTANCE: invention refers to medicine, biorhythmology. Method of long-term self-control of arterial pressure and pulse involves measuring of AP and pulse every hour in 5 replications every 2 minutes for 10 minutes: 1st measurement is carried out immediately after tonometer switching on, 2nd – at 2 minute, 3d – at 4 minute, 4th – at 6 minute, 5th – at 8 minute during 16 hours: from 7.45 to 23. During measuring it is necessary to take into account biological rhythms – measurement is performed, when the Moon at passes the same constellation annually in same months twice – in winter and summer, in same or neighboring lunar day. Measurement is made accurately 15 minutes before end of every hour. From obtained data average daily values of AP and pulse are calculated, plot dependence of SISav – age (year) and PULav – age (year) are drawn.EFFECT: method allows any adult during whole life to perform long-term individual control of arterial pressure and pulse and timely respond to their change.1 cl, 6 ex, 6 tbl, 6 dwg
Attenuated strain "msc-2015 vniivvim" of african swine fever virus serotype viii for virology and molecular-genetic analysis // 2607791
FIELD: medicine.SUBSTANCE: invention relates to virology. Attenuated strain “SKA-2015 VNIIVViM” of african swine fever virus serotype VIII is disclosed. Strain is produced by intermittent passages and selection of virulent strain "Stavropol 01/08" in primary cell culture of LS and transplantable hybrid cell line A4C2/9k and it is deposited in State collection of strains of microorganisms GNU Rosselhozakademii VNIIVViM under No. 1847.EFFECT: strain "MSC-2015 VNIIVViM" can be used during virological, molecular-genetic research, studying immunogenesis of disease, development of diagnostic and vaccine preparations.1 cl, 4 tbl, 4 ex
Novel pyrrole compounds, synthesis method thereof and pharmaceutical compositions containing same // 2607788
FIELD: chemistry.SUBSTANCE: invention relates to a compound of formula (I) possessing inhibitory activity on Bcl-2 family proteins. In formula (I) (I) A1 is hydrogen, (C1-C6)polyhaloalkyl group or (C1-C6)alkyl group, A2 is hydrogen, (C1-C6)polyhaloalkyl group, (C1-C6)alkyl group or cycloalkyl group, T denotes a hydrogen atom, (C1-C6)alkyl group, optionally substituted with one-three halogen atoms, group (C1-C4)alkyl-NR1R2 or group (C1-C4)alkyl-OR6, R1 and R2 each independently from each other is a hydrogen atom or (C1-C6)alkyl group, or R1 and R2 form with a nitrogen atom bearing them, heterocycloalkyl, R3 is (C1-C6)alkyl group, cycloalkyl group, heterocycloalkyl group, aryl group or heteroaryl group, wherein one or more carbon atoms of previous groups or their possible substitutes can be deuterated, R4 is an aryl group or heteroaryl group, wherein one or more carbon atoms of previous groups or their possible substitutes can be deuterated, R5 is hydrogen or halogen atom, R6 is a hydrogen atom or a linear or branched (C1-C6)alkyl group, Ra, Rb, Rc and Rd each independently from other represents hydrogen, linear or branched (C1-C6)alkyl, halogen atom, a linear or branched (C1-C6)alkoxy group, hydroxy group, R7-CO-NH-(C0-C6)alkyl-, R7-SO2-NH-(C0-C6)alkyl-, R7-NH-CO-NH-(C0-C6)alkyl-, R7-O-CO-NH-(C0-C6)alkyl-, or substitutes of pair (Rb, Rc) form together with carbon atoms carrying them, a ring consisting of 5–6 ring members, which may contain 1–2 oxygen atoms, R7 is hydrogen, linear or branched (C1-C6)alkyl, aryl or heteroaryl. Invention also relates to methods of producing compounds of formula (I), to a pharmaceutical composition, use of a pharmaceutical composition for preparing a drug, use of compound of formula (I) for preparing a drug.EFFECT: obtaining novel compounds of formula (I) possessing inhibitory activity on Bcl-2 family proteins.37 cl, 2 tbl, 473 ex
ethod of therapeutic-preventive agent delivery articles production // 2607777
FIELD: materials.SUBSTANCE: layered material from non-woven materials, including fine solid particles connected to it, is produced by deposition method, using which delivery to approximately 60 g/m2 of solid particles to substrate is possible. Solid particles can be applied onto substrate by means of powder application plant.EFFECT: layered material can be used in absorbent items for personal use, such as diapers, female sanitary pads, bandaging materials, mattress pads, etc.11 cl, 15 dwg, 4 tbl
ethod of package production sensitive to adhesive tape pressure // 2607749
FIELD: packaging industry.SUBSTANCE: group of inventions relates to production of package sensitive to adhesive tape pressure, suitable for industrial production (versions). Method of package production sensitive to adhesive tape pressure, which represents sensitive to adhesive tape pressure package 10, in which sensitive to pressure adhesive tape 14 is arranged. Latter comprises substrate 18 and adhesive layer 12, deposited on one substrate surface 18. Sensitive to pressure adhesive tape package also comprises anti-adhesion sheet 16, on which adhesive tape adhesive layer is fixed with possibility of anti-adhesion sheet subsequent removal. In this method adhesive tape 14 is attached to anti-adhesion sheet 116 main material and folded in halves. Then plurality of adhesive tapes 14 is subjected to heat sealing and temporarily attached to one anti-adhesion sheet 116 main material and anti-adhesion sheet 116 primary material is cut.EFFECT: technical result achieved when using method according to invention consists in order to improve production efficiency.8 cl, 24 dwg
ethod of film stretching // 2607742
FIELD: manufacturing technology.SUBSTANCE: invention relates to laminated material producing method containing non-woven fabric and film. This method comprises heating initial thermoplastic polymer material film, containing at least one low-melting polymer component and at least one high-melting polymer component, until at least partially melted state. At that, at least one low-melting polymer component is in melted liquid state, and at least one high-melting polymer component is not in melted liquid state. Melting is performed by means of at least one heating cylinder. Then performing cooled by passing of partially melted film via cooled cylinders clamp. Film is stretched between at least one heating cylinder and cooled cylinders clamp. Produced films can be laminated together with nonwoven material. Laminated material is used in medicine or hygiene fields.EFFECT: technical result achieved when using method and laminated material according to inventions, consists in production of thinner films.9 cl, 1 dwg, 3 tbl, 1 ex
Rectal suppositories with analgesic action // 2607661
FIELD: medicine.SUBSTANCE: invention relates to medicine, in particular to drugs, and can be used for production of rectal suppositories for relieving of pain of various origin: postoperative pain, vertebrogenic radicular pain, arthritis, cancer pain, cardialgia, headache, dysmenorrhea, kidney and liver colics. Rectal suppositories proposed by authors have analgesic action and contain preparation of non-steroidal row and base, differing by fact, that preparation of non-steroidal row contains ketorolac and additionally contains amitriptyline, while base contains silicon glicerolates in 3-molar excess of glycerine composition Si(C3H7O3)4⋅3C3H8O3 and polyethylene glycol PEG-4000 with following ratio of components, calculated in g per one suppository: ketorolac 0.021÷0.031, amitriptyline 0.003÷0.008, PEG-4000 1.793÷1.804, silicon glicerolates 0.768÷0.773.EFFECT: production of rectal suppositories.1 cl, 2 tbl, 2 ex
Composition comprising an antibiotic and a dispersant or an anti-adhesive agent // 2607660
FIELD: medicine.SUBSTANCE: invention relates to products for treating or preventing of bacterial infection, comprising an antibiotic agent and a second agent representing a dispersant or an anti-adhesive agent, where antibiotic is a tobramycin, colistin, gentamycin or ciprofloxacin, and a dispersant or an anti-adhesive agent is a cysteamine.EFFECT: treatment or prevention of bacterial infection.1 cl, 10 dwg, 2 tbl, 2 ex
Transdermal therapeutic system for 5-aminolevulinic acid hydrochloride // 2607657
FIELD: medicine.SUBSTANCE: group of inventions relates to medicine. Disclosed is transdermal therapeutic system, which includes active substance impermeable back layer, containing active substance, polymer matrix and separable protective layer, wherein active substance is represented by 5-aminolevulinic acid hydrochloride and polymer matrix basic polymer is adhesive polyacrylate. Transdermal therapeutic system is applicable for diagnosing and treating of skin cancer pre-stages, such as actinic keratosis, as well as skin oncological diseases.EFFECT: transdermal therapeutic system is fairly well sticks to skin and does not cause irritation thereof.15 cl, 1 dwg, 4 ex
ethod of producing dalfampridin tablets with prolonged action // 2607655
FIELD: pharmaceutics.SUBSTANCE: invention relates to chemical-pharmaceutical industry and medicine. Method of producing dalfampridin pellets is disclosed, characterized by preparing intra-granulated mixture by screening dalfampridin together with hydroxypropyl methyl cellulose with viscosity of 80–120 MPA˙s, mixing with microcrystalline cellulose with particle size of 50–90 mcm and aerosil, compaction, mixing with magnesium stearate, it is followed by granulation of mixture by rolling, extra-granulated mixture is added to obtained granules consisting of microcrystalline cellulose with particle size of 50–90 mcm and aerosil, mixed to homogeneous state, magnesium stearate is added, tablets are pressed and coated with their shell by spraying water solution of white Opadraja till tablet weight increases by 1.0–3.0 %.EFFECT: obtained solid shape has improved pharmacological and process characteristics.6 cl, 1 dwg, 3 tbl, 3 ex
ethod of producing nanocapsules of adenine in carrageenan // 2607654
FIELD: nanotechnology.SUBSTANCE: invention relates to a method of producing nanocapsules of adenine. Specified method is characterized by that carrageenan in benzene is added with glycerol ester with one or two molecules of edible fatty acids and one or two molecules of citric acid as a surfactant, the produced mixture is stirred, added with adenine powder, after formation of an independent solid phase is slowly added with petroleum ether, the produced suspension of nanocapsules is filtered, washed with petroleum ether and dried, herewith the ratio of nucleus/shell in the nanocapsules makes 1:3, 1:1 or 5:1.EFFECT: invention provides faster and easier process of nanoencapsulation of adenine, as well as higher mass output.1 cl, 1 dwg, 4 ex
ethod for simulating bone-reconstructive surgeries in treating new growths of jaw bone in childhood // 2607651
FIELD: medicine.SUBSTANCE: invention relates to medicine, namely, to maxillofacial surgery and orthodontics. For simulating bone-reconstructive surgeries in treating new growths of jaw bone in childhood is carried out KT examination of skull with subsequent reconstruction in 3D programs and create a three-dimensional model of skull, identify new growth, calculate basic parametric data of neoplasms and virtually it is removed in the resulting model, then virtually fill a defect or flaw, then prototyping reconstructive models of jaws or endoprosthesis using a 3D printer. For virtual removal of neoplasm is performed a 3D cephalometry, on the received 3D model of skull manually placed cephalometric marks at maximum increase of screen resolution, using simultaneously different projections, perspective, right, left, top, front and by varying the transparency of the image from 0 to 100 %, determined 48 cephalometric parameters against which is carried out a virtual replacement of defect or flaw zone with subsequent virtual correction of jaw bones during the staged orthodontic-surgical treatment.EFFECT: method allows to simulate and predict the staged surgical-orthodontic and orthopaedic treatment in a child until its growth, as well as reduce a probability of unplanned step operations.1 cl, 21 dwg, 4 tbl, 1 ex
Full spectrum led illuminator // 2607645
FIELD: lighting.SUBSTANCE: invention relates to lighting engineering. Device for outputting light to a light guide to illuminate an imaged object comprises a plurality of solid-state light-emitting sources, each independently supplied with energy, independently controlled and emits light at wavelength, different from wavelengths emitted by other light-emitting sources. Device also includes a heat sink configured for thermal coupling of plurality of solid-state light-emitting sources and conduction of heat formed by plurality of solid-state light-emitting sources, optical elements intended for collection, collimation and combination of radiation from plurality of solid-state light-emitting sources into a combined light beam, intended for optical coupling with light guide.EFFECT: higher illumination brightness with full spectrum of visible radiation.4 cl, 4 dwg
N-9-substituted purine compounds, compositions and methods of use // 2607635
FIELD: chemistry.SUBSTANCE: present invention relates to novel compounds of formula I-A, having properties of inhibitors of kinase of phosphoinositide-3-kinase family mTOR and PI3K, for use in treating cancer, as well as for preparing drugs for treating cancer. In compounds of formula I-A R1 is selected from a group comprising cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, azetidin-1-yl, azetidin-2-yl, azetidin-3-yl, pyrrolidin-1-yl, pyrrolidin-2-yl, pyrrolidin-3-yl, piperidin-1-yl, piperidin-2-yl, piperidin-3-yl, piperidin-4-yl, oxetan-2-yl, oxetan-3-yl, tetrahydrofuran-2-yl, tetrahydrofuran-3-yl, tetrahydropyran-2-yl, tetrahydropyran-3-yl and tetrahydropyran-4-yl, oxepan-2-yl, oxepan-3-yl, oxepan-4-yl, phenyl pyrrol-2-yl, pyrrol-3-yl, pyrazol-3-yl, pyrazol-4-yl, pyrazol-5-yl, furan-2-yl, furan-3-yl, thien-2-yl, thien-3-yl, thiazol-2-yl, thiazol-3-yl, thiazol-4-yl, imidazol-1-yl, imidazol-4-yl, pyrid-2-yl, pyrid-3-yl, pyrid-4-yl, pyrimidin-1-yl, pyrimidin-2-yl, pyrimidin-3-yl, pyrazin-2-yl, pyridazin-2-yl, pyridazin-3-yl and triazin-2-yl, where R1 substituted by 0-3 substitutes RR1, selected from a group consisting of halogen, F, Cl, Br, I, -ORa, -C(O)Ra, -Rc; where Ra is selected from hydrogen or C1-6alkyl, Rc is C1-6alkyl; R2 is selected from a group comprising hydrogen, C1-6alkyl, C2-6alkenyl, C2-6alkynyl; R3 is a morpholine-4-yl, where group R3 is substituted with 0–3 substitutes RR3, selected from a group consisting of -Ri, halogen, where Ri is selected from C1-6alkyl, C1-6haloalkyl; D is -NR4C(O)NR5R6 or -NR5R6, where R4 and R5 each denotes hydrogen and R6 is C1-6alkyl, C1-6haloalkyl oxetan-3-yl and pyridyl-on.EFFECT: treatment of cancer.11 cl, 1 tbl, 26 ex
Romidepsin solid forms and use thereof // 2607634
FIELD: chemistry.SUBSTANCE: invention relates to novel crystalline form C of romidepsin, a pharmaceutical composition containing form C of romidepsin.EFFECT: treatment of skin T-cell lymphoma.3 cl, 12 dwg, 19 tbl, 16 ex
Aromatic derivatives of sulfanilamides carbonic anhydrase ii (ca ii) inhibitors, methods for production and use thereof // 2607630
FIELD: chemistry.SUBSTANCE: present invention relates to novel aromatic sulphonamide derivatives, general formula 1 and pharmaceutically acceptable salts thereof, which are selective inhibitors of carbonic anhydrase II (CA II). Substituted sulphonamides correspond to general formula 1 ,where A is phenyl or thiophene; R1 is C1-C5alkyl, C-3C6cycloalkyl, -C(O)R3; provided that R1 is not methyl, when A is phenyl, R2 represents hydrogen; R3 is a 5-6 member heterocyclyl with one or two heteroatoms, selected from nitrogen or oxygen atoms; R2 is C1-C3alkyl, C1-C3alkoxy. Invention also relates to a method of producing compounds of general formula 1. Method involves two stages: a) sulphochlorination of corresponding oxazole derivative of general formula 5 (a-o) or 6 (a-j) with a mixture chlorosulphonic acid and thionyl chloride to produce intermediate sulphochlorides of formula 7 (a-o) or 8 (a-j), respectively, and b) with subsequent conversion of obtained sulphochlorides into primary sulphamides of formula 9 (b-o) or 10 (a-j) by reacting with ammonia according to following scheme ,where ,where R1 is C1-C5alkyl, C3-C6cycloalkyl; NR'Rʺ is a morpholine or pyrrolidine.EFFECT: compounds can be used for treating glaucoma, in particular, open-angle glaucoma, and other diseases caused by high intraocular pressure, age-related macular degeneration, diabetic macular edema, diabetic retinopathy, hypertensive retinopathy and retinal vasculopathy mediated by activity of carbonic anhydrase II.11 cl, 2 dwg, 2 tbl, 57 ex
Sodium salt of 2-methylthio-6-cyano-1,2,4-triazolo[5,1-c]-1,2,4-triazin-7(4h)-one, trihydrate // 2607628
FIELD: chemistry.SUBSTANCE: invention relates to a sodium salt of 2-methylthio-6-cyano-1,2,4-triazolo[5,1-c]-1,2,4-triazin-7(4H)-one, trihydrate, which exhibits antiviral action on influenza .EFFECT: obtaining a novel compound having antiviral activity.1 cl, 1 dwg, 2 tbl, 4 ex
Leg for surgical table // 2607607
FIELD: medicine.SUBSTANCE: invention relates to surgical table leg. Leg of surgical table comprises at least two sliding transport rollers. Surgical table in retracted position of transport rollers stands on support element of surgical table. Surgical table in extended position of transport rollers can move on rollers. There is first mechanical setting unit, by means of which position of first transport roller can vary, at least, from retracted position to extended position. There is second mechanical setting unit, by means of which position of second transport roller can vary, at least, from retracted position to extended position. First mounting unit and second mounting unit can be driven by first drive unit, which is connected by mechanically coupled mean to first and second mounting units. Mechanical coupler is chain or belt, wherein first and second mounting units are connected to first drive unit by means of chain or belt.EFFECT: invention aims at simplified use of legs surgical table.16 cl, 11 dwg
ethod of producing hybrid two-phase system of delivery of poorly soluble and insoluble in water biologically active substances with controlled release kinetic // 2607598
FIELD: pharmaceutics.SUBSTANCE: group of inventions relates to pharmaceutical industry, namely, to system of delivery of poorly soluble and insoluble biologically active substances (BAS) with controlled release kinetics, which is spherical nanoparticles containing hydrophobic core formed of biocompatible and biodegradable hydrophobic polymers, such as polyhydroxybutyrate, polylactide, polyglycolide, polydioxanone, poly-ε-caprolactone, polyhydroxyvalerate, copolymer of lactic and glycolic acids, in which there is a partially soluble or insoluble in water BAS; wherein hydrophobic core is surrounded with hydrophilic fragments of amphiphilic polymers consisting of one fragment of water-soluble carbon chain polymer with molecular weight Mn=1,000-30,000 Da and one end hydrophobic group, including one aliphatic radical with carbon atoms number in carbon chain 9÷20, as well as to method of producing such system of delivery.EFFECT: group of inventions provides higher water compatibility of poorly soluble and insoluble BAS, increased stability of medicinal substances and possibility of controlling release rate of BAS.6 cl, 7 ex, 6 tbl, 15 dwg
ultiple emulsion // 2607597
FIELD: pharmaceutics.SUBSTANCE: invention refers to pharmaceutical and cosmetic industry and represents multiple emulsion for application of at least one pharmaceutical or cosmetic active substance, which includes external aqueous phase W1, oil phase O, dispersed in external aqueous phase, and inner aqueous phase W2 dispersed in oil phase O, where in inner aqueous phase W2 there is at least one electrolyte, selected from group of alkali and alkali-earth metals halides and sulphates, and at least one hydrophilic active substance, where multiple emulsion is characterized by, that external aqueous phase W1 contains hydrophilic emulsifier, which is ethylene oxide and propylene oxide polymer, oil phase O is formed by triacylglycerols and contains lipophilic emulsifier from dimeticones group, and hydrophilic active substance, which is oligonucleotide having sequence according to SEQ ID No: 1 – SEQ ID No: 148 or SEQ ID No: 150.EFFECT: invention provides high stability, efficient protection of active substances against external effects and protection against microorganisms damages.20 cl, 1 tbl, 3 dwg
Combined anticancer therapy // 2607596
FIELD: medicine.SUBSTANCE: present invention relates to combined therapy with {3-[5-(4-chlorophenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4difluorophenyl} amide of propane-1-sulphonic acid (compound 1) or its pharmaceutically acceptable salt and EGFR inhibitor, selected from erlotinib and cetuximab, for treating cancer, containing b-Raf with V600 mutation, namely colorectal cancer, melanoma and thyroid cancer.EFFECT: combination of compound 1 with EGFR inhibitor leads to improved anti-tumor effects, which considerably exceed the results, obtained for each compound separately, without increasing the toxicity.20 cl, 6 ex, 15 tbl, 9 dwg
Rasagiline compositions of prolonged release and use thereof // 2607595
FIELD: pharmaceutics.SUBSTANCE: group of inventions refers to pharmaceutics. Oral pharmaceutical composition is described in form of prolonged release for treating neurodegenerative disease or damage of nervous system. Above composition contains R(+)-N-propargyl-1-aminoindan (rasagiline) as active substance. Composition contains pellets with prolonged release and pharmaceutically acceptable carrier. Said pellet includes: I) inert core of pellet; II) layer with active substance, polyvinyl pyrrolidone and talc; III) optionally insulating layer with polyvinyl pyrrolidone; IV) prolonged release coating layer with ethylcellulose and polyethylene glycol. Use of said composition and method of treating neurodegenerative disease or damage of nervous system are also described.EFFECT: invention provides intensified effect on above diseases.16 cl, 9 dwg, 17 tbl, 11 ex
Combination of ozogamicin inotuzumab and torizel for treating cancer // 2607594
FIELD: medicine.SUBSTANCE: invention relates to therapeutic method of treating cancer, which is non-Hodgkin’s lymphoma; method involves stage of introducing simultaneously or successively effective number of ozogamicin inotuzumab (SMS-544) in dose of 0.4 mg/m2 up to 1.8 mg/m2 every 4 weeks throughout 6 cycles and temsirolimus in dose of 5 to 175 mg/week during disease progression.EFFECT: invention provides low toxicity, associated with treatment using ozogamicin inotuzumab or temsirolimus.7 cl, 8 ex, 11 tbl
ethod for prevention of postoperative complications accompanying surgical management of patients with congenital malformations of external and middle ear // 2607593
FIELD: medicine.SUBSTANCE: invention relates to medicine, namely to otorhinolaryngology, and can be used for prevention of postoperative complications accompanying surgical management of patients with congenital malformations of external and middle ear. For this purpose, during the early postoperative period the ear is being cleaned, and the external acoustic meatus is being washed with an octenisept solution diluted in distilled water 1:5. Then, a session of endaural electrophoresis is performed with the Longidaza solution for 10–30 minutes. After the session of electrophoresis, a turunda impregnated with a mixture of preparations "Longidaza" and "Fermenkol" gel, 0.5 ml of each is being introduced into the external acoustic meatus. Turunda is being introduced 3 times a day for 10–15 days.EFFECT: invention enables reducing the treating period and preventing commissure formation in the external acoustic meatus.1 cl, 2 ex
New pharmaceutical composition containing nsaid and cyclodextrin // 2607592
FIELD: medicine.SUBSTANCE: invention refers to medicine and consists in liquid composition for treating sore throat, containing 1–5 % wt/vol. of flurbiprofen; 5–10 % wt/vol. of cyclodextrin; up to 5 % wt/vol. of buffer agents and 80–90 % wt/vol. of water.EFFECT: technical result consists in physically and chemically pure stable solution of flurbiprofen of sufficient concentration, solution has no undesirable taste and does not contain alcohol as auxiliary solvent.21 cl, 5 ex, 2 tbl, 5 dwg
Biologically active additive for making cosmetics // 2607591
FIELD: cosmetology.SUBSTANCE: invention refers to cosmetic industry and represents a biologically active additive for making cosmetic compositions, containing modified dextrane and cosmetically acceptable carrier, differing by the fact, that dekstranal with molecular weight 20–75 kDa is used as modified dextran, wherein ingredients of additive are taken in certain proportions, wt%.EFFECT: invention provides anti-inflammatory and moisturizing effect with simultaneous improvement of elastometry and profilometry of skin.3 cl, 4 ex, 4 tbl
ethod of treating chronic endometritis // 2607590
FIELD: medicine.SUBSTANCE: invention relates to medicine, namely to gynecology, and can be used for treating chronic endometritis. For that integrated two-step exposure on endometrium is performed. At first stage system anti-inflammatory therapy is carried out and then intrauterine introduction of Categel with lidocaine in 3–4 instillations at 12.5 g every second day within therapeutic course. At second stage is anti-fiberizing preparation Longidase is introduced in form of vaginal suppositories, one suppository 1 time in 3 days – 10 suppositories per therapeutic course.EFFECT: invention enables to increase efficiency of treatment of chronic endometritis due to complex two-stage exposure on endometrium.1 cl, 4 tbl
ethod of producing nanocapsules of amino acids in konjac gum // 2607589
FIELD: chemistry.SUBSTANCE: invention relates to encapsulation. Described is a method of producing nanocapsules of L-arginine or norvaline. Shell of nanocapsules used is konjak gum. According to disclosed method, L-arginine or norvaline is added to suspension konjak gum in butyl alcohol in presence of an E472c preparation, at a weight ratio of core: shell 5:1 or 1:3, or 1:1 respectively. Ethyl acetate is then added. Obtained suspension of nanocapsules is filtered and dried.EFFECT: invention provides a simpler and faster process of producing nanocapsules, reduces losses during production thereof (high mass output).1 cl, 1 dwg, 7 ex
ethod of producing functionalised imaging agents with anti-stokes photoluminescence based on polyacrolein dispersions // 2607587
FIELD: chemistry.SUBSTANCE: invention relates to chemistry of high-molecular compounds and a method of producing imaging agents with anti-Stokes photoluminescence in form of an aqueous dispersion of polyacrolein particles, containing nano-sized anti-Stokes phosphors, by polymerisation of acrolein in aqueous alkaline medium, carried out in two steps, first of which comprises settling polymerisation, and at second step obtained product undergoes further radical polymerisation in presence of a water-soluble initiator K2S2O8, characterised by that first polymerisation step is carried out i presence of anti-Stokes phosphors in amount of 0.1–1.5 wt% with respect to monomer, pre-treated with tetramethylammonium hydroxide, which are used as a polymerisation initiator.EFFECT: invention makes it possible to encapsulate nanosized anti-Stokes phosphors in volume of polymer matrix, which protects optical properties of nanophosphors from biological media and provides colloid-chemical properties required for use as imaging agents in biological analysis and biological imaging. 1 cl, 1 tbl, 4 ex
Biocompatible nanomaterial for photosensitivity singlet oxygen and method for production thereof // 2607579
FIELD: medicine.SUBSTANCE: group of inventions refers to medicine, in particular to oncology, and describes a biocompatible nanomaterial and method of its production. Proposed biocompatible nanomaterial is a hybrid associates of colloidal quantum dots CdS with average size of 2–4 nm with cations of methylene blue (MB+) in concentration 10-1–10-4 (νpaints/νCdS). Method involves double jet merging of 0.6–5 % solution of sodium sulphide and 0.8–7 % solution of cadmium bromide with melt of gelatin with producing of colloidal solution, containing colloidal quantum dots of CdS, solution is held at temperature of 4–10 °C, produced gelatine jelly is crushed to grain with size 5–10 mm, washed in distilled water at temperature from 7 to 13 °C for 30 minutes, decant excess water and granules are heated to temperature above 40°C. Nanomaterial is highly efficient generation of singlet oxygen and satisfactory parameters of cytotoxicity, testifies to its biocompatibility.EFFECT: invention can be used in medicine and biology for photodynamic therapy of oncological and other human diseases.2 cl, 6 dwg
Compositions and methods for treating and diagnosing asthma // 2607569
FIELD: biotechnology.SUBSTANCE: invention relates to biotechnology, immunology and medicine. Application of antibody binding to IL-13 is disclosed as medicinal agent for treating asthma in humans. Wherein patient has high expression levels of POSTN in relation to average or median level of POSTN expression. Method of treating asthma subtype using such antibodies is also described.EFFECT: disclosed group of inventions can be used in medicine.23 cl, 49 dwg, 13 tbl, 9 ex
ethod of radial bone distal end plastics // 2607567
FIELD: medicine.SUBSTANCE: invention relates to traumatology and orthopedics and can be used for repair of distal end of radial bone. Autograft is taken from fibular bone, including section of thumb flexor muscle of foot, which is sutured to muscle long flexor muscle of thumb. Distal end of autograft is modelled with rasp for congruence with semilunar bone of wrist, which is fixed to it with transosseous capron suture at level of dissected transverse carpal ligament. Autograft and ulnar bone are clamp type covered and fixed with lavsan tape. Autograft is fixed to radial bone with reconstructive plate with angular stability.EFFECT: method enables creating conditions for reparative osteogenesis, restore congruence of articular surfaces.1 cl, 2 dwg
Lithium silicate glass ceramics and glass with hexavalent metal oxide // 2607557
FIELD: ceramic industry.SUBSTANCE: invention relates to lithium silicate glass ceramic and glass, which are crystallized at low temperatures and are especially suitable as dental materials, in particular, for dental restoration. Lithium silicate glass ceramics contains hexavalent metal oxide, selected from MoO3, WO3 and mixtures thereof, in amount of 0.1–8.4 wt%, from 12.0 to 20.0 wt% of Li2O and wherein including from 0 to less than 0.5 wt% of K2O. For production of glass ceramics with lithium disilicate as main crystalline phase initial glass with germs is subjected to thermal treatment at temperature of 520–750 °C.EFFECT: technical result of invention is production of glass ceramic with improved mechanical and optical properties.22 cl, 1 tbl, 9 ex
Device for controlling the height of the operating table // 2607553
FIELD: medicine; manufacturing technology.SUBSTANCE: invention relates to a device for regulating the height of the operating table. Support comprises operating table slide moving relative to chassis, main guide with the first longitudinal axis around which the slide can rotate, the auxiliary guide with the second longitudinal axis and the guiding device which is connected to the chassis of the operating table and which has a contact area in which the guiding device is in contact with the auxiliary guide in the contact area of the auxiliary guide. Main and auxiliary guides are used to control the lift movement of the slide within the control range of the slide in a direction parallel to the first longitudinal axis, wherein the plane perpendicular to the first longitudinal axis through the guiding device has a first point of intersection with the first longitudinal axis and the second point of intersection with the second longitudinal axis, wherein the position of the second intersection point during the implementation of the slider lifting movement in its control range varies along the path. Connection between the guiding device and chassis allow for a smooth movement of the guiding device in such a way, that the contact area of the guiding device can move along the path.EFFECT: invention is intended for higher reliability of device.15 cl, 9 dwg
Closure system for non-spill feeding bottle for children // 2607551
FIELD: personal usage items.SUBSTANCE: invention relates to a closure system for a non-spill feeding bottle for children, with a lower closure ring, which has a substantially cylindrical lower jacket part with an inner thread that can be screwed onto an outer thread of a bottle, and a lower partition wall which, above inner thread, is connected at edge to lower jacket part, blocks off cross section of lower jacket part, and has a first top face and a first bottom face with at least one lower through-hole opening out, on one hand, in first top face, and, on other hand, in first bottom face, an upper closure ring, which has a substantially cylindrical upper jacket part with an outer thread, that can be connected to a screw ring in order to secure a teat on upper edge of upper jacket part, and an upper partition wall which is connected at edge to upper jacket part, blocks off cross section of upper jacket part, and has a second top face and, sitting sealingly on first top face, a second bottom face with at least one upper through-hole opening out, on one hand, in second bottom face, and on other hand, in second top face, locking elements with which lower closure ring and upper closure ring are locked onto each other. On lower partition wall in a tight manner over opening in lower partition wall there is at least one sealing pad made of soft elastic material, so that it blocks cross section of opening and is tightly connected with lower partition wall, and in second lower side of upper partition wall there is at least one upper through hole with sealing seat corresponding to contour of sealing pad, wherein by turning upper closing ring relative to lower locking ring, upper through hole can be selectively brought into position of mutual overlapping or non-overlapping relative to lower through hole, and sealing seat can be brought into sealing position relative to sealing pad.EFFECT: disclosed is a closure system for a non-spill feeding bottle for children.15 cl, 32 dwg
Absorbent article including two dimensional code made from active graphic // 2607548
FIELD: information technology.SUBSTANCE: described are absorbent articles that convey information to a user. In particular, absorbent articles include an active graphic that comprises a machine readable code. Active graphic, for instance, may comprise a disappearing graphic, an appearing graphic, and/or a colour-change graphic. Change in appearance of graphic may occur once contacted with a suitable activation agent, such as urine.EFFECT: machine readable code contained in active graphic, once scanned by a suitable reader device, may convey information to a user related to absorbent article.15 cl, 6 dwg
Surgical staple cassettes and end effectors with devices for vessels measuring // 2607530
FIELD: medicine.SUBSTANCE: invention relates to medicine and can be used for assessment of tissue, cross-linked with staple cassette, or processed with end effector otherwise. Staple cassette has at least one series of measurement scale marks, located on panel base. Marks can be seen from above in relation to panel surface, when detent presses tissue to staple cassette.EFFECT: marks on panel of cassette correspond to dimensions of tissue, placed on it.19 cl, 9 dwg
Auto-injector // 2607529
FIELD: medical equipment.SUBSTANCE: invention relates to medical equipment, particularly, to an auto-injector for administering a dose of a liquid medicament. Injector comprises an elongate case arranged to be held by a user, tubular chassis telescopable in the case and biased against the case so as to protrude from the case, syringe with a hollow injection needle, drive spring and a plunger for forwarding load of the drive spring to a stopper of the syringe, trigger button which is initially abutted against the case preventing actuation, wherein the chassis is arranged to translate into the case against the pressed bias, wherein the trigger button is at least initially coupled to the chassis in such a manner that the trigger button emerges from the case, when the chassis is being translated towards the case for starting an injection cycle, trigger button is arranged distally in or on the case, carrier subassembly comprises a tubular carrier slidably arranged relative to the chassis inside the case, carrier adapted to contain the syringe with the hollow injection needle, the drive spring and the plunger, wherein the syringe is lockable for joint axial translation with the carrier, wherein the trigger button is initially coupled to the chassis through the carrier by the trigger button abutting the carrier, and the carrier being coupled to the chassis by a detent mechanism, wherein the a detent mechanism is arranged for coupling the chassis to the carrier for joint axial translation relative to the case, wherein the detent mechanism is arranged to decouple the chassis from the carrier upon actuation of the trigger button, thus allowing the carrier to move relative to the chassis.EFFECT: administering a dose of a liquid medicament.23 cl, 27 dwg
Auto-injector // 2607528
FIELD: medicine.SUBSTANCE: invention refers to medical equipment, namely to injection devices, and in particular, to auto-injectors. Auto-injector for administering a dose of a liquid medicament contains an elongate tubular case and carrier subassembly. Carrier subassembly comprising a tubular carrier slidably arranged inside the case. Carrier adapted to contain a syringe with a hollow injection needle, drive spring and plunger for forwarding load of the drive spring to a stopper of the syringe. Syringe is lockable for joint axial translation with the carrier. Drive spring acts between the carrier and the plunger. Plunger in the initial state is locked to the carrier by a ramped engagement to the carrier and by being prevented from rotating out of this ramped engagement, depending on a relative longitudinal position of the carrier in the case. Plunger is arranged to be released for rotating out of the ramped engagement upon the needle reaching at least, nearly a predefined injection depth, on translation of the carrier in the proximal direction for advancing the needle beyond a proximal end of the auto-injector.EFFECT: invention has a mechanism for unlocking the plunger, which is especially reliable and efficient method of starting injection drug after the needle reaching an injection depth, excluding so called wet injection, id est medicament leaking out the needle, which is a problem in conventional auto-injectors, where both needle insertion and injection are achieved by pushing on the stopper.25 cl, 27 dwg
Covalent monoconjugate of polyethylene glycol with thymosin beta 4, resistant to degradation in bloodstream and method for its production // 2607527
FIELD: biotechnology.SUBSTANCE: group of inventions relates to biotechnology and can be used in medicine and pharmaceutical industry. Method for regioselective chemical N-terminal PEGylation of thymosin beta 4. By this method monoconjugate of PEG with thymosin beta 4 is obtained, having improved pharmacokinetic properties. Modification of N-terminal alpha amino group of thymosin beta 4 is confirmed.EFFECT: use of invention enables to obtain monoPEGylated thymosin beta 4 with high output.2 cl, 4 dwg, 3 ex
Lipopeptide composition and related methods // 2607526
FIELD: pharmaceutics.SUBSTANCE: invention relates to solid pharmaceutical compositions of daptomycin for treating bacterial infections. Above composition is obtained by freeze-drying or spray drying of aqueous solution of daptomycin or buffer composition of daptomycin containing daptomycin and at least one excipient selected from sucrose or trehalose, wherein molar ratio of daptomycin to excipient ranges from 1:1.12 to 1:21.32. Invention also relates to production and use of said compositions.EFFECT: invention provides faster restoration of lyophilized composition of daptomycin in aqueous pharmaceutical diluent, as well as high chemical stability of daptomycin both in form of solid substance and in reduced liquid phases.25 cl, 8 dwg, 5 tbl, 6 ex
Implant with surface with calcium and methods of modifying surface of implant to provide said surface with calcium // 2607525
FIELD: medicine.SUBSTANCE: invention relates to implant for human or animal body, which contains on its outer surface at least one calcium salt, soluble in polar liquid. Invention also relates to method of deliberate initiation of blood coagulation, arising when actuating outer surface of implant in contact with blood.EFFECT: calcium ions, contained on implant surface, provide specified surface with four chemically and biologically useful effects: hydrophilic properties, protection against contamination in contact with atmosphere, procoagulation property and mineralization property.8 cl, 14 dwg, 1 tbl
Quaternary ammonium salts based on derivatives of vitamin b6 // 2607522
FIELD: medicine.SUBSTANCE: invention relates to novel derivatives of vitamin B6 of general formula (I) with high antibacterial activity. ,where at R1=R4=N+(CH3)2C8H17, R2+R3=-C(CH3)2O-, R5=H, n=2, m=0; at R1=R4=N+(CH3)2C12H25, R2+R3=-C(CH3)2O-, R5=H, n=2, m=0; at R1=R4=N+(CH3)2C18H37, R2+R3=-C(CH3)2O-, R5=H, n=2, m=0; at R1=R4=N+(CH3)2C8H17, R2=R5=H, R3=OH, n=2, m=1; at R1=R4=N+(CH3)2C12H25, R2=R5=H, R3=OH, n=2, m=1; at R1=R4=N+(CH3)2C18H37, R2=R5=H, R3=OH, n=2, m=1; at R1=R5=H, R2+R3=-CH(C2H5)O-, R4=N+(CH3)2C18H37, n=1, m=0; at R1=R5=H, R2+R3=-CH(C3H7)O-, R4=N+(CH3)2C18H37, n=1, m=0; at R1=R5=H, R2+R3=-CH(C4H9)O-, R4=N+(CH3)2C18H37, n=1, m=0; at R1=R5=H, R2+R3=-CH(C(CH3)3)O-, R4=N+(CH3)2C18H37, n=1, m=0; at R1=R5=H, R2+R3=-CH(C8H17)O-, R4=N+(CH3)2C18H37, n=1, m=0; at R1=R5=H, R2+R3=-CH(CH2CH(CH3)C9H19)O-, R4=N+(CH3)2C18H37, n=1, m=0; at R1=R5=H, R2+R3=-CH2O-, R4=N+(CH3)2C18H37, n=1, m=0; at R1=R5=H, R2+R3=-C(cycle-C4H8)O-, R4=N+(CH3)2C18H37, n=1, m=0; at R1=R5=H, R2+R3=-CH(C3H7)O-, R4=N+(CH3)2C8H17, n=1, m=0; at R1=R5=H, R2+R3=-CH(C3H7)O-, R4=N+(CH3)2C12H25, n=1, m=0; at R1=R5=H, R2+R3=-CH2O-, R4=N+(CH3)2C8H17, n=1, m=0; at R1=R5=H, R2+R3=-CH2O-, R4=N+(CH3)2C12H25, n=1, m=0; at R1=R5=H, R2+R3=-C(CH3)2O-, R4=N+(CH3)2C12H25, n=1, m=0; at R1=R2=R5=H, R3=OH, R4=N+(CH3)2C12H25, n=1, m=1; at R1=R3=R5=H, R2=C(O)CH3, R4=N+(CH3)2C8H17, n=1, m=0; at R1=R3=R5=H, R2=C(O)CH3, R4=N+(CH3)2C12H25, n=1, m=0; at R1=R3=R5=H, R2=C(O)CH3, R4=N+(CH3)2C18H37, n=1, m=0; at R1=R2=R3=R5=H, R4=N+(CH3)2C8H17, n=1, m=1; at R1=R2=R3=R5=H, R4=N+(CH3)2C12H25, n=1, m=1; at R1=R2=R3=R5=H, R4=N+(CH3)2C18H37, n=1, m=1; at R1=N+(CH3)2C8H17, R2+R3=-C(CH3)2O-, R4+R5=-OC(CH3)2OCH2-, n=1, m=0; at R1=N+(CH3)2C18H37, R2+R3=-C(CH3)2O-, R4+R5=-OC(CH3)2OCH2-, n=1, m=0; at R1=N+(CH3)2C8H17, R2+R3=-C(CH3)2O-, R4=OH, R5=CH2OH, n=1, m=1; at R1=N+(CH3)2C18H37, R2=H, R3=R4=OH, R5=CH2OH, n=1, m=1.EFFECT: invention can be used in medicine and veterinary science.1 cl, 2 tbl, 30 ex
Partial gold salt of polyacrylic acid, method for production thereof and agent based thereon, having haemostatic action when used externally // 2607519
FIELD: chemistry.SUBSTANCE: invention relates to novel chemical compounds, which can be used in chemistry and medicine as a haemostatic agents. Disclosed is a partial gold salt of polyacrylic acid, characterised by that it corresponds to formula: ,where n = 1,100–3,800; m = 100–800. Also disclosed is a method of producing a compound in paragraph 1, method is characterised by that it comprises adding to solution of polyacrylic acid an aqueous solution of aurichlorohydric acid, reaction mixture is mixed for 60 more minutes, obtained solution is dried in vacuum at temperature not higher than 50 °C. Disclosed is an agent, containing incomplete gold salt of polyacrylic acid, having haemostatic action for external application.EFFECT: technical result is solution has good adhesion to wound surface, effectively stops bleeding, bleeding does not resume when film is removed.3 cl, 7 ex
Crystalline form of sodium salt of 4-tert-butyl-n-[4-chloro-2-(1-oxy-pyridine-4-carbonyl)-phenyl]-benzenesulfonamide // 2607515
FIELD: chemistry.SUBSTANCE: invention relates to a novel crystalline form of a sodium salt of 4-tert-butyl-N-[4-chloro-2-(1- oxy-pyridine-4-carbonyl)-phenyl]-benzenesulphonamide.EFFECT: said crystalline form can be used in treating inflammatory bowel disease.19 cl, 10 dwg, 2 tbl, 3 ex
Polymorphic forms of sodium salt of 4-tert-butyl-n-[4-chloro-2-(1-oxy-pyridine-4-carbonyl)-phenyl]-benzenesulphonamide // 2607514
FIELD: chemistry.SUBSTANCE: invention relates to novel polymorphic trihydrated forms of sodium salt of 4-tert-butyl-N-[4-chloro-2-(1-oxy-pyridine-4-carbonyl)-phenyl] benzenesulphonamide.EFFECT: disclosed polymorphic forms can be used for treating inflammatory bowel disease.10 cl, 8 dwg, 2 tbl, 3 ex
Needle-free connector with compressed elastic membrane insert and corresponding method // 2607513
FIELD: medicine.SUBSTANCE: group of inventions relates to medical equipment. Needle-free connector for passage of liquid medium contains valve body with first and second holes. Inner surface of valve passes between holes and forms cavity. Hollow elastic membrane is located in valve body and has first and second ends, between which elastic membrane extends longitudinally. Second end has through hole opening into second hole. Side surface of membrane passes between first and second ends and it is located inside valve body. Side surface forms inner cavity of hollow elastic membrane. Inner cavity extends longitudinally from through slot located on first end to through hole at second end. Slot is closed, when first end is located in first hole so that it closes first hole. Slot is open, when first end is pushed into valve body to create passage for liquid medium through first end and cavity to second end. Outer surface of side surface of elastic membrane is in contact with inner surface of valve body so, that forms cavity with volume less than 1 % of inner cavity. Drug container and unit for passage of liquid medium including needle-free connector are disclosed.EFFECT: invention provides minimization of space of drugs non-mixing.15 cl, 18 dwg
ethod for gastrointestinal tract reconstruction in case of chronic duodenal ileus // 2607512
FIELD: medicine.SUBSTANCE: invention relates to medicine, surgery. In case of abnormal duodenal passage, caused by chronic duodenal ileus, vagotomy is being performed. Stomach is being dissected away at the boundary between the middle and upper thirds. Duodenum is being transected 2 cm more distally than a pyloric sphincter. Roux jejunal loop is being formed transecting it at a distance of 40 cm from the ligament of Treitz. “end-to-end” duodeno-enteroanastomosis is being formed with the end of the Roux jejunum. Gastroenteroanastomosis and jejuno-jejuno anastomosis are being used.EFFECT: method provides an adequate passage along the gastrointestinal tract bypassing the stenotic portion of duodenum simultaneously with decompression of the latter.1 cl, 11 dwg, 1 ex
Staple unit containing tissue thickness compensator // 2607511
FIELD: medicine.SUBSTANCE: invention relates to medicine. Unit with cross-linking elements comprises support part, tissue thickness compensator, located relative to support part, and multiple cross-linking elements, located inside support part and/or tissue thickness compensator. During use unit with cross-linking elements is placed in first branch of surgical suturing device. Second branch or thrust is set opposite to first branch. For actuation of cross-linking elements in working position element, which actuates staples in working position, moves through unit with cross-linking elements for moving of cross-linking elements to thrust.EFFECT: after placement cross-linking elements grip at least part of tissue thickness compensator together with at least part of sutured tissue.22 cl, 389 dwg
Automated measurement of doppler velocity using cheap converter // 2607510
FIELD: medicine.SUBSTANCE: group of inventions relates to medical equipment, namely to ultrasonic examination of blood vessels of body. Ultrasonic device for analyzing fluid medium for implementation of ultrasonic analysis comprises ultrasonic probe for volume analysis and control circuit, configured to perform steps, on which if during examination one or more blood vessels are found inside volume, blood vessel for analysis of fluid medium flow is selected from blood vessels found inside volume, information specifically relating to selected vessel is formed, further, it is specified whether selected vessel is target vessel, if it is, then indication is provided with respect to normal state of fluid flow in selected vessel, otherwise selection, formation and determination are repeated for the next blood vessel from found vessels until no other next blood vessel is found inside volume, wherein said actions do not depend on displaying images of ultrasonic scanning and are automatical without any need of user intervention. Computer-readable data medium contains computer program, wherein computer program instructions are executed by processor for performing actions of method.EFFECT: this group of inventions allows to expand range of technical means.11 cl, 3 dwg
 
2551319.
Up!